Cardarine (GW-501516) Capsules

Buy Cardarine (GW-501516) Online

Cardarine, also known as GW-501516 or GW1516, is a synthetic PPARδ agonist that has attracted substantial research interest for its effects on fatty-acid metabolism, energy utilization, and exercise-related metabolic pathways. Although often discussed alongside SARMs, Cardarine is not a SARM because it does not act through the androgen receptor.

Product Information

Cardarine selectively activates peroxisome proliferator-activated receptor delta (PPARδ), a nuclear receptor involved in regulating lipid metabolism and energy expenditure. Research has demonstrated that PPARδ activation can increase fatty-acid oxidation and alter metabolic pathways in skeletal muscle.

The compound became particularly well known for research involving endurance and metabolic performance. However, its development was discontinued after long-term animal studies raised serious safety concerns, and it has no established therapeutic use in humans.

How It Works

Cardarine activates PPARδ, which regulates genes involved in fatty-acid utilization and energy metabolism. By shifting cellular metabolism toward greater lipid utilization, GW-501516 has been investigated for its ability to influence endurance, metabolic flexibility, and exercise-related adaptations.

POTENTIAL BENEFITS

1. Endurance Research

Cardarine is particularly well known for its potential effects on endurance-related pathways. PPARδ activation promotes metabolic changes associated with greater oxidative capacity, making GW-501516 a widely studied compound in research examining prolonged physical performance.

2. Fatty-Acid Oxidation

One of the central research interests surrounding Cardarine is its ability to influence fatty-acid oxidation. By activating PPARδ, the compound can alter the expression of genes involved in lipid utilization and energy production, making it valuable for metabolic research.

3. Metabolic Research

PPARδ is involved in several aspects of energy metabolism, including lipid handling and skeletal-muscle fuel utilization. Cardarine has therefore been studied as a tool for investigating metabolic flexibility and how changes in cellular fuel preference affect overall energy regulation.

4. Exercise-Metabolism Research

Research involving GW-501516 has helped researchers examine how pharmacological activation of PPARδ can produce metabolic adaptations associated with exercise. This makes Cardarine particularly relevant to studies investigating the relationship between energy metabolism, skeletal muscle, and endurance performance.

5. Lipid-Metabolism Research

Cardarine's effects on PPARδ have generated interest in lipid-related research, including fatty-acid utilization and cholesterol metabolism. Its ability to alter metabolic gene expression provides researchers with a useful model for studying how nuclear-receptor activation can influence lipid handling throughout the body.

Dosage

There is no medically established human dosage for Cardarine.

A PubMed-indexed doping-control study reports that oral performance-enhancement use has involved 10–20 mg per day for approximately 6–8 weeks. These figures describe reported use rather than an established safe or recommended human dose.

Community reports also commonly mention 10–20 mg per day, with some users reporting 10 mg as a starting amount. These reports are anecdotal and should not be interpreted as medically validated dosing.

Side Effects

Cardarine has important safety concerns, particularly because of findings from long-term animal research. Potential concerns include:

• Unknown long-term human safety
• Possible liver-related effects
• Unknown cardiovascular consequences
• Potential metabolic effects
• Serious toxicity concerns identified in animal studies

Long-term animal studies raised concerns about tumor development, which contributed to the discontinuation of Cardarine's drug development. The compound also remains prohibited by the World Anti-Doping Agency.

References

• Dressel U, et al. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol. 2003. PMID: 14525954. PubMed
• Zembron-Lacny A, et al. Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and AICAR. Biol Sport. 2014. PMID: 25179079. PubMed
• Testing for GW501516 (Cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS. Drug Test Anal. 2020. PMID: 32298044. PubMed
• Sanchis-Gomar F, et al. PPARδ Modulation by GW501516: An Unsuccessful Exercise Mimetic. Clin Pharmacol Ther. 2017. PMID: 28124448. PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.

re-shared by Ahmad 2026-09-03 as "the rewrite"; flagged then as unchanged/still "Liquid"-titled

(see build-manifest.md row 9). Re-read 2026-09-04: content has since changed — H1 is now just

"Cardarine (GW-501516)" (no "Liquid"), body text differs from the live Liquid product's

description throughout. Ahmad appears to have edited the doc in place after being told it was

wrong (same pattern as the YK-11 fix). Now generic/form-agnostic, which fits today's standing

rule (generic PD -> one simple product, never per-variation) — no longer blocked on "needs an

actual capsule-form rewrite." -->

Please click here to access instructions on how to make a payment.

How to Pay